OpenBit ResearchOpenBit
中文

What's driving Cytokinetics (CYTK)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Cytokinetics Aficamten ACACIA-HCM Commercial Translation

Why it matters now

A pivotal Phase 3 efficacy result can improve the regulatory and commercial value of Cytokinetics' aficamten program.

Next checkpoint

CYTK earnings (expected 2026-11-04)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to CYTK, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Subsequent evidence fails to reproduce meaningful benefits or regulatory or development action prevents aficamten from advancing toward commercialization.

Research drivers

  • Cytokinetics Aficamten ACACIA-HCM Commercial Translation

    Bullish · Active · Updated

    Aficamten's positive pivotal results support continued clinical and commercial development in non-obstructive hypertrophic cardiomyopathy.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • B. Riley Securities analyst Mayank Mamtani said investors might be reacting to the size of the win rather than whether the trial won.

    Relayed by: Benzinga · Event date on record:

  • The ACACIA-HCM Phase 3 trial achieved its dual primary endpoints, with substantial improvements after 36 weeks versus placebo in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and maximal exercise performance.

    Relayed by: Benzinga · Event date on record:

  • 53% of patients treated with aficamten achieved a clinical response in three or more measurement areas, compared with 13% of placebo patients.

    Relayed by: Benzinga · Event date on record:

  • Cytokinetics' Chief Medical Officer Stephen Heitner said the findings highlight the potential impact aficamten could have on patients with non-obstructive hypertrophic cardiomyopathy independent of relief of left ventricular outfl

    Relayed by: Benzinga · Event date on record:

  • Cytokinetics announced that additional results from the ACACIA-HCM and MAPLE-HCM trials were presented in a Late Breaking Clinical Session at the European Society of Cardiology Congress 2026 and simultaneously published in Circula

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.